Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001611024-25-000004
Filing Date
2025-11-12
Accepted
2025-11-12 16:37:30
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10472
2 ex-99-11122025_091132.htm EX-99.1 14086
  Complete submission text file 0001611024-25-000004.txt   26038
Mailing Address C/O ALLOGENE THERAPEUTICS, INC. 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address
Chang David D (Filed by) CIK: 0001611024 (see all company filings)

Type: SCHEDULE 13G/A

Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Subject) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90685 | Film No.: 251473596
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)